TipRanks
Advertisement
Advertisement

FR:MAAT Stock Latest News

MaaT Pharma Refocuses MaaT013 on Global Phase 3 Trial After EMA Setback
Company AnnouncementsMaaT Pharma Refocuses MaaT013 on Global Phase 3 Trial After EMA Setback
3m ago
MAAT
MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD
PremiumCompany Announcements
MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD
3d ago
MAAT
MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential
PremiumRatings
MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential
6M ago
Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus
PremiumRatings
Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus
1y ago
Buy Rating for MaaT Pharma Driven by Promising Clinical Developments and Strategic Financial Projections
PremiumRatings
Buy Rating for MaaT Pharma Driven by Promising Clinical Developments and Strategic Financial Projections
1y ago
Buy Rating for MaaT Pharma: Promising Phase 3 Results and Strategic Growth Catalysts
PremiumRatingsBuy Rating for MaaT Pharma: Promising Phase 3 Results and Strategic Growth Catalysts
1y ago
MaaT Pharma’s Strong Financial Position and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
MaaT Pharma’s Strong Financial Position and Promising Clinical Developments Drive Buy Rating
1y ago
MaaT Pharma’s Promising Outlook: Buy Rating Backed by Positive DSMB Review and Strong Phase 3 Results for MaaT013
Premium
Ratings
MaaT Pharma’s Promising Outlook: Buy Rating Backed by Positive DSMB Review and Strong Phase 3 Results for MaaT013
2y ago
MaaT Pharma: Buy Rating Affirmed Amid Promising Regulatory Milestones and Market Potential
PremiumRatingsMaaT Pharma: Buy Rating Affirmed Amid Promising Regulatory Milestones and Market Potential
2y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >